Kintor Pharmaceutical shares surged 147% on news of Covid-19 drug efficacy
Kintor Pharmaceutical shares surged 147% on news of Covid-19 drug efficacy
$KINTOR PHARMA-B(09939.HK)$ shares soared in Hong Kong trading after the company said a new drug proved effective in treating Covid-19 patients.
$金達醫藥-B(09939.HK)$在該公司宣佈一種新藥被證明對治療新冠肺炎患者有效後，該公司股價在香港交易中飆升。
Shares of the Chinese drug developer more than doubled after initally jumping 229% closer to the open on Wednesday. The $KINTOR PHARMA-B(09939.HK)$ increased 147.5% to 34.60 as at 10.59 am.
這家中國醫藥開發商的股價在週三開盤時上漲了229%，漲幅超過一倍。這個$金達醫藥-B(09939.HK)$截至上午10時59分，增長147.5%至34.6
Kintor said before the start of trading that a clinical trial for its proxalutamide drug candidate had effectively reduced the risk of hospitalization and death in outpatients with mild-to-moderate cases of Covid-19, including patients with high-risk factors such as older age.
Kintor在開盤前表示，其候選丙沙魯胺藥物的臨牀試驗有效地降低了新冠肺炎輕中度病例(包括年齡等高危因素患者)門診患者的住院和死亡風險。
The drug also provided some relief to Covid-19-related symptoms such as fever, shortness of breath and coughing.
該藥還對新冠肺炎相關症狀有一定緩解作用，如發燒、呼吸急促和咳嗽。
It said there were no serious adverse reactions among patients in the Phase 3 study, which examined more than 700 patients mainly from the U.S.
該公司表示，在第三階段研究中，患者沒有出現嚴重的不良反應，該研究檢查了700多名主要來自美國的患者。
Write to Ben Otto at ben.otto@wsj.com
寫信給Ben Otto，電子郵件：ben.otto@wsj.com